Protocol Ledger

NCT05840562 · Phase III · RECRUITING

Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy

Interventional Phase III clinical trial protocol NCT05840562 sponsored by Institut Cancerologie de l'Ouest in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-10-20 Enrollment: 274 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05840562
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)274 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05840562
Protocol FieldVerified Registry Value
NCT IdentifierNCT05840562
Consolidated Lead SponsorInstitut Cancerologie de l'Ouest
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment274 participants (ESTIMATED)
Registered Start Date2023-10-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05840562
Hospital Research SiteLocationSite Profile
Centre François BaclesseCaen, FranceOpen Hospital Dossier ->
Centre Léon BérardLyon, FranceOpen Hospital Dossier ->
Centre Antoine-LacassagneNice, FranceOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI